Feb 21 (Reuters) – The U.S. Food and Drug Administration approved Lundbeck A/S’ migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.
For Lundbeck, the approval opens doors to a lucrative but competitive market dominated by already approved rivals from Amgen Inc, Teva Pharmaceutical Industries Ltd and Eli Lilly and Co.
Reporting by Manas Mishra and Mrinalika Roy in Bengaluru;
Additional reporting by Akshay Balan in Bengaluru; Editing by
Shinjini Ganguli and Sandra Maler